Kingsoft Cloud's 15min Chart Shows MACD Death Cross and Narrowing Bollinger Bands.

Kingsoft Cloud's 15-minute chart has recently triggered a MACD Death Cross and Bollinger Bands Narrowing on October 16, 2025 at 14:30. This suggests that the stock price may continue to decline and the magnitude of stock price fluctuations may decrease.

As the financial markets continue to seek out profitable innovations, particularly in the healthcare and biotech sectors, two underappreciated stocks are quietly gaining traction: Ardelyx (ARDX) and TScan Therapeutics (TCRX). Both companies have shown promise through revenue growth, expanding margins, and promising pipelines, positioning them as potential winners in 2025.

Ardelyx (ARDX)
Ardelyx, valued at $1.17 billion, is a small-cap biotech company focusing on gastrointestinal (GI) tract drugs with minimal systemic absorption. Its two main commercial medications, IBSRELA and XPHOZAH, have shown substantial revenue growth. In the second quarter, Ardelyx reported $97.7 million in total revenue, up 33% year-over-year (YoY) and 32% sequentially. IBSRELA, which treats irritable bowel syndrome with constipation (IBS-C), generated $65 million in net sales, reflecting an 84% YoY increase. Ardelyx's 2025 IBSRELA sales projection has been increased to $250 million to $260 million, according to a Barchart article.

XPHOZAH, used to reduce serum phosphate levels in individuals with chronic kidney disease (CKD) on dialysis, also saw net sales of $25 million in the second quarter. Ardelyx is expanding its reach globally through partnerships, such as those with Kyowa Kirin in Japan and Fosun Pharma in China. Despite a net loss of $19.1 million in the second quarter, Ardelyx ended the period with $238.5 million in cash, cash equivalents, and investments, providing flexibility for future development. Wall Street analysts rate Ardelyx stock a consensus "Strong Buy," with an average price target of $11.36, suggesting a potential 123% increase from current levels, which the Barchart article also reported.

TScan Therapeutics (TCRX)
TScan Therapeutics, valued at $119.4 million, is a clinical-stage biotech company advancing modified T cell receptor (TCR-T) therapies. This strategy uses a patient's immune system to target and remove cancer cells. TScan has two active programs: the ALLOHATrial investigating TSC-101 to treat blood malignancies, and the PLEXI-T Trial aiming to treat solid tumors with multiplex TCR-T treatment. Management aims to develop a scalable, commercial-ready method for its therapies, decreasing manufacturing time and costs. In the second quarter, TScan made $3.1 million in sales, primarily from its collaboration with Amgen, and ended the period with a cash balance of $218 million.

If the ALLOHA Phase 1 findings indicate lower relapse rates in blood cancers and the PLEXI-T solid tumor trial shows early efficacy, TScan could become a key player in the next wave of immuno-oncology innovation. Wall Street analysts rate TCRX stock a consensus "Strong Buy," with an average price target of $8.57, suggesting a potential 300% increase over the next 12 months.

Conclusion
While Ardelyx and TScan Therapeutics may not yet be household names, their fundamentals and promising pipelines make them worth watching in 2025. Both companies have shown strong revenue growth and expanding margins, positioning them for long-term success. Investors should keep an eye on these underappreciated stocks as they continue to develop their products and expand their reach.

References
- Barchart — 2 Overlooked Stocks to Snap Up in 2025: https://www.barchart.com/story/news/35491404/2-overlooked-stocks-to-snap-up-in-2025